NASDAQ:MDNA Medicenna Therapeutics (MDNA) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.16▼$0.3952-Week Range N/AVolume1.27 million shsAverage Volume160,047 shsMarket Capitalization$10.93 millionP/E RatioN/ADividend YieldN/APrice Target$2.75 Stock AnalysisStock Analysis Get Medicenna Therapeutics alerts: Email Address Medicenna Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside∞ Upside$2.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.17) to ($0.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.79 out of 5 starsMedical Sector856th out of 936 stocksPharmaceutical Preparations Industry400th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingMedicenna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMedicenna Therapeutics has received no research coverage in the past 90 days.Read more about Medicenna Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for MDNA. Previous Next 0.0 Dividend Strength Dividend YieldMedicenna Therapeutics does not currently pay a dividend.Dividend GrowthMedicenna Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDNA. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Medicenna Therapeutics this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medicenna Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders33.10% of the stock of Medicenna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.38% of the stock of Medicenna Therapeutics is held by institutions.Read more about Medicenna Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Medicenna Therapeutics are expected to decrease in the coming year, from ($0.17) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medicenna Therapeutics is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medicenna Therapeutics is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! About Medicenna Therapeutics Stock (NASDAQ:MDNA)Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.Read More Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! MDNA Stock News HeadlinesJuly 24 at 12:02 PM | theglobeandmail.comClosing Bell: Medicenna Therapeutics Corp flat on Tuesday (MDNA)May 26, 2024 | finance.yahoo.comMedicenna Therapeutics Corp. (MDNA.TO)July 27, 2024 | DTI (Ad)Heard about the 72-Hour Profit Surge? Read this…One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…May 13, 2024 | seekingalpha.comMDNA:CA Medicenna Therapeutics Corp.May 10, 2024 | investing.comMedicenna Therapeutics Corp (MDNA)April 30, 2024 | finance.yahoo.comMedicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital ManagementApril 24, 2024 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual MeetingApril 11, 2024 | investing.comMedicenna reports advancement in cancer immunotherapyJuly 27, 2024 | DTI (Ad)Heard about the 72-Hour Profit Surge? Read this…One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…April 4, 2024 | finance.yahoo.comMedicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceMarch 1, 2024 | morningstar.comMedicenna Therapeutics Corp MDNAFebruary 14, 2024 | finance.yahoo.comMedicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate UpdateJanuary 12, 2024 | tmcnet.comMedicenna Announces Appointment of New AuditorDecember 19, 2023 | finance.yahoo.comMedicenna Announces Trading on the OTCQB Under the Symbol MDNAFNovember 20, 2023 | finance.yahoo.comMDNA.TO: Overall Survival Data from Phase 2b Trial of Bizaxofusp Presented at SNO 2023…November 14, 2023 | finance.yahoo.comMedicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational HighlightsNovember 13, 2023 | finance.yahoo.comMDNA.TO: Additional Confirmed PR in Phase 1/2 ABILITY Trial of MDNA11November 6, 2023 | finance.yahoo.comMedicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)See More Headlines Receive MDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today7/27/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MDNA CUSIPN/A CIK1807983 Webwww.medicenna.com Phone(416) 648-5555Fax416-572-7501Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$2.75 High Stock Price Target$3.00 Low Stock Price Target$2.50 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.68% Return on Assets-35.17% Debt Debt-to-Equity RatioN/A Current Ratio9.57 Quick Ratio9.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / BookN/AMiscellaneous Outstanding Shares69,637,000Free Float46,587,000Market Cap$10.93 million OptionableNot Optionable Beta1.30 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Fahar Merchant Ph.D. (Age 66)Founder, Chairman, President & CEO Comp: $327.41kMs. Rosemina Merchant B.Sc. (Age 66)M.E.Sc, Founder & Chief Development Officer Comp: $262.62kMr. Jeff Caravella M.B.A.Chief Financial OfficerMr. Brent Meadows M.B.A.Chief Business OfficerDr. Humphrey A. R. Gardner FCAPM.D., Chief Medical OfficerDr. Samuel R. Denmeade M.D.Scientific AdvisorMore ExecutivesKey CompetitorsMarker TherapeuticsNASDAQ:MRKRCalciMedicaNASDAQ:CALCTempest TherapeuticsNASDAQ:TPSTProMIS NeurosciencesNASDAQ:PMNAadi BioscienceNASDAQ:AADIView All Competitors MDNA Stock Analysis - Frequently Asked Questions How were Medicenna Therapeutics' earnings last quarter? Medicenna Therapeutics Corp. (NASDAQ:MDNA) posted its earnings results on Friday, November, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03. This page (NASDAQ:MDNA) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicenna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
